Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) was up 0.1% during mid-day trading on Tuesday . The stock traded as high as $0.69 and last traded at $0.68. Approximately 172,854 shares were traded during trading, a decline of 89% from the average daily volume of 1,557,632 shares. The stock had previously closed at $0.68.
Salarius Pharmaceuticals Stock Performance
The stock has a market cap of $1.45 million, a P/E ratio of -0.14 and a beta of 0.44. The stock’s fifty day moving average is $0.83 and its 200 day moving average is $1.18.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.37.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
- Five stocks we like better than Salarius Pharmaceuticals
- 5 discounted opportunities for dividend growth investors
- JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth
- What Are Treasury Bonds?
- Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
- What is a Stock Market Index and How Do You Use Them?
- Fastenal Surges After Earnings Beat, Tariff Risks Loom
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
